- Home
- ACET vs ICCM Comparison
ACET vs ICCM Comparison
Compare ACET & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- ICCM
- Stock Information
- Founded
- ACET 1947
- ICCM 2006
- Country
- ACET United States
- ICCM Israel
- Employees
- ACET N/A
- ICCM N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- ACET Health Care
- ICCM
- Exchange
- ACET Nasdaq
- ICCM Nasdaq
- Market Cap
- ACET 64.9M
- ICCM 59.9M
- IPO Year
- ACET N/A
- ICCM N/A
- Fundamental
- Price
- ACET $0.61
- ICCM $1.07
- Analyst Decision
- ACET Buy
- ICCM Strong Buy
- Analyst Count
- ACET 6
- ICCM 1
- Target Price
- ACET $6.00
- ICCM $2.50
- AVG Volume (30 Days)
- ACET 398.4K
- ICCM 321.2K
- Earning Date
- ACET 08-12-2025
- ICCM 08-19-2025
- Dividend Yield
- ACET N/A
- ICCM N/A
- EPS Growth
- ACET N/A
- ICCM N/A
- EPS
- ACET N/A
- ICCM N/A
- Revenue
- ACET N/A
- ICCM $3,273,000.00
- Revenue This Year
- ACET N/A
- ICCM $83.41
- Revenue Next Year
- ACET N/A
- ICCM $185.02
- P/E Ratio
- ACET N/A
- ICCM N/A
- Revenue Growth
- ACET N/A
- ICCM 0.34
- 52 Week Low
- ACET $0.45
- ICCM $0.48
- 52 Week High
- ACET $1.70
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- ACET 38.76
- ICCM 56.78
- Support Level
- ACET $0.61
- ICCM $0.96
- Resistance Level
- ACET $0.69
- ICCM $1.03
- Average True Range (ATR)
- ACET 0.04
- ICCM 0.07
- MACD
- ACET -0.01
- ICCM 0.01
- Stochastic Oscillator
- ACET 12.80
- ICCM 87.81
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.